Peroxisome proliferator-activated receptor (PPAR) agonists are U.S. Food and Drug Administration (FDA)-approved drugs indicated for use in type 2 diabetes and dyslipidemia [8,9]. This evidence concerns the gene PPARA and metabolic syndrome.